155 related articles for article (PubMed ID: 29698701)
21. Mucinous phenotype and CD10 expression of primary adenocarcinoma of the small intestine.
Kumagai R; Kohashi K; Takahashi S; Yamamoto H; Hirahashi M; Taguchi K; Nishiyama K; Oda Y
World J Gastroenterol; 2015 Mar; 21(9):2700-10. PubMed ID: 25759539
[TBL] [Abstract][Full Text] [Related]
22. Characterization of intrahepatic cholangiocarcinoma of the intraductal growth-type and its precursor lesions.
Yeh TS; Tseng JH; Chen TC; Liu NJ; Chiu CT; Jan YY; Chen MF
Hepatology; 2005 Sep; 42(3):657-64. PubMed ID: 16116640
[TBL] [Abstract][Full Text] [Related]
23. Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct--an immunohistochemical study of 110 cases of hepatolithiasis.
Zen Y; Sasaki M; Fujii T; Chen TC; Chen MF; Yeh TS; Jan YY; Huang SF; Nimura Y; Nakanuma Y
J Hepatol; 2006 Feb; 44(2):350-8. PubMed ID: 16360234
[TBL] [Abstract][Full Text] [Related]
24. S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas.
Tsai JH; Huang WC; Kuo KT; Yuan RH; Chen YL; Jeng YM
Histopathology; 2012 Dec; 61(6):1106-16. PubMed ID: 22882148
[TBL] [Abstract][Full Text] [Related]
25. Expression of insulin-like growth factor II mRNA-binding protein 3 predicts early recurrence and poor prognosis in intrahepatic cholangiocarcinoma.
Chen YL; Jeng YM; Hsu HC; Lai HS; Lee PH; Lai PL; Yuan RH
Int J Surg; 2013; 11(1):85-91. PubMed ID: 23246869
[TBL] [Abstract][Full Text] [Related]
26. Intrahepatic cholangiocarcinoma: new insights in pathology.
Sempoux C; Jibara G; Ward SC; Fan C; Qin L; Roayaie S; Fiel MI; Schwartz M; Thung SN
Semin Liver Dis; 2011 Feb; 31(1):49-60. PubMed ID: 21344350
[TBL] [Abstract][Full Text] [Related]
27. Cholangiolar pattern and albumin in situ hybridisation enable a diagnosis of intrahepatic cholangiocarcinoma.
Brackett DG; Neyaz A; Arora K; Masia R; Mattia A; Zukerberg L; Misdraji J; Goyal L; Zhu AX; Ferrone CR; Yilmaz OH; Deshpande V
J Clin Pathol; 2020 Jan; 73(1):23-29. PubMed ID: 31422372
[TBL] [Abstract][Full Text] [Related]
28. Diffuse expression of MUC6 defines a distinct clinicopathological subset of pulmonary invasive mucinous adenocarcinoma.
Kishikawa S; Hayashi T; Saito T; Takamochi K; Kohsaka S; Sano K; Sasahara N; Sasa K; Kurihara T; Hara K; Suehara Y; Takahashi F; Suzuki K; Yao T
Mod Pathol; 2021 Apr; 34(4):786-797. PubMed ID: 33024306
[TBL] [Abstract][Full Text] [Related]
29. Intrahepatic cholangiocarcinoma with multicystic, mucinous appearance and oncocytic change.
Fujii T; Harada K; Katayanagi K; Kurumaya H; Nakanuma Y
Pathol Int; 2005 Apr; 55(4):206-9. PubMed ID: 15826247
[TBL] [Abstract][Full Text] [Related]
30. Gastric mucin phenotype defines tumour progression and prognosis of intrahepatic cholangiocarcinoma: gastric foveolar type is associated with aggressive tumour behaviour.
Aishima S; Kuroda Y; Nishihara Y; Taguchi K; Taketomi A; Maehara Y; Tsuneyoshi M
Histopathology; 2006 Jul; 49(1):35-44. PubMed ID: 16842244
[TBL] [Abstract][Full Text] [Related]
31. MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma.
Boonla C; Sripa B; Thuwajit P; Cha-On U; Puapairoj A; Miwa M; Wongkham S
World J Gastroenterol; 2005 Aug; 11(32):4939-46. PubMed ID: 16124042
[TBL] [Abstract][Full Text] [Related]
32. Prognostic evaluation of mucin-5AC expression in intrahepatic cholangiocarcinoma, mass-forming type, following hepatectomy.
Abe T; Amano H; Shimamoto F; Hattori M; Kuroda S; Kobayashi T; Tashiro H; Ohdan H
Eur J Surg Oncol; 2015 Nov; 41(11):1515-21. PubMed ID: 26210654
[TBL] [Abstract][Full Text] [Related]
33. Defining the biology of intrahepatic cholangiocarcinoma: molecular pathways and early detection of precursor lesions.
Gibiino G; Fabbri C; Fagiuoli S; Ianiro G; Fornelli A; Cennamo V
Eur Rev Med Pharmacol Sci; 2017 Feb; 21(4):730-741. PubMed ID: 28272710
[TBL] [Abstract][Full Text] [Related]
34. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
[TBL] [Abstract][Full Text] [Related]
35. Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance.
Shimonishi T; Isse K; Shibata F; Aburatani I; Tsuneyama K; Sabit H; Harada K; Miyazaki K; Nakanuma Y
Hepatology; 2000 Oct; 32(4 Pt 1):761-9. PubMed ID: 11003620
[TBL] [Abstract][Full Text] [Related]
36. Inactivation of Smad4 is a prognostic factor in intrahepatic cholangiocarcinoma.
Yan XQ; Zhang W; Zhang BX; Liang HF; Zhang WG; Chen XP
Chin Med J (Engl); 2013 Aug; 126(16):3039-43. PubMed ID: 23981608
[TBL] [Abstract][Full Text] [Related]
37. Imaging findings of mucinous type of cholangiocellular carcinoma.
Hayashi M; Matsui O; Ueda K; Kadoya M; Yoshikawa J; Gabata T; Takashima T; Izumi R; Nakanuma Y
J Comput Assist Tomogr; 1996; 20(3):386-9. PubMed ID: 8626896
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemistry in the Diagnosis of Mucinous Neoplasms Involving the Ovary: The Added Value of SATB2 and Biomarker Discovery Through Protein Expression Database Mining.
Strickland S; Wasserman JK; Giassi A; Djordjevic B; Parra-Herran C
Int J Gynecol Pathol; 2016 May; 35(3):191-208. PubMed ID: 26535987
[TBL] [Abstract][Full Text] [Related]
39. Elevation of serum γ-glutamyltransferase as a predictor of aggressive tumor behaviors and unfavorable prognosis in patients with intrahepatic cholangiocarcinoma: analysis of a large monocenter study.
Yin X; Zheng SS; Zhang BH; Zhou Y; Chen XH; Ren ZG; Qiu SJ; Fan J
Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1408-14. PubMed ID: 23839159
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma.
Okuda H; Shiratori K; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2006 May; 21(5):869-73. PubMed ID: 16704538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
